Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

21 July 2020: Articles

High-Dose Prednisone for Treatment of Autoimmune Pancreatitis in a Patient with Coronavirus Disease 2019 (COVID-19) due to Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Unusual clinical course, Unusual setting of medical care

Hammad Liaquat A* , Brittney Shupp B , Sarina Kapoor C , Ayaz Matin A

DOI: 10.12659/AJCR.926475

Am J Case Rep 2020; 21:e926475

Table 2. Studies demonstrating outcomes of corticosteroid treatment in patients with coronavirus disease 2019 (COVID-19) due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

OutbreakParticipantsMethodsOutcomes related to steroid useRef
SER-CoV-2138 hospitalized patients with confirmed COVID-19 infection, including 45% who received methylprednisoloneReviewed clinical data of COVID-19 patients to identify, analyze, and compare patient characteristics and treatment outcomesNo effective outcomes were observed[]7
41 hospitalized patients with confirmed COVID-19 infection, including 22% who received methylprednisoloneReviewed clinical data of COVID-19 patients to identify, analyze, and compare patient characteristics, radiographic features, and laboratory dataMethylprednisolone was administered if patient was diagnosed with severe community acquired pneumonia, but no effective outcomes were observed[]22
201 hospitalized patients with confirmed COVID-19 infection, including 30.8% who received methylprednisoloneReviewed clinical data of COVID-19 patients to identify, analyze, and compare patient characteristics, radiographic features, and laboratory dataDeath rates in ARDS patients who did and did not receive methylprednisolone were 46% and 61.8%, respectively[]23
15 hospitalized patients with critical COVID-19 pneumonia admitted to the ICUInitiated corticosteroid treatment after ICU stay of an average of 9.5 days and followed up on patient outcomesUse of corticosteroids did not improve ICU mortality. No conclusion on corticosteroid usage could be reached due to small sample size and lack of a matched control group[]21
46 hospitalized patients with severe COVID-19 pneumonia, including 26 who received extra low-dose methylprednisolone treatmentCompared the clinical outcomes of patients receiving low dose methylprednisolone treatment with a control group that received the same treatment regimen without methylprednisoloneUse of low dose and short term methylprednisolone treatment early in the disease course was associated with better outcomes in severe COVID-19 patients including shorter supplemental oxygen use, reduced need for mechanical ventilation, and shorter ICU and hospitalization stay[]20

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923